Ixico plc provided earning guidance for the fiscal year 2020. The Board is now confirmed that the impact of COVID-19 on the Company's expected financial performance for fiscal year 2020 has been modest, and it is confident of achieving at least £9.1 million revenues and £0.9 million earnings before interest, tax, depreciation and amortisation ('EBITDA') with positive operating cash for the year ended 30 September 2020. This would represent a fourth consecutive year of revenue growth of 20% or more and an increase in EBITDA margin from 6% to 10% compared to the prior year, despite COVID-19 disruptions to clinical trial timelines. The Board also expects the Company to continue to maintain double-digit revenue growth across fiscal year 2021 whilst continuing to invest to ensure the Company is ready to scale as those clinical trials delayed due to the COVID-19 crisis are initiated.